WallStSmart

Carvana Co (CVNA)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 31% more annual revenue ($29.44B vs $22.52B). GILD leads profitability with a 28.9% profit margin vs 6.4%. GILD trades at a lower P/E of 18.2x. GILD earns a higher WallStSmart Score of 72/100 (B).

CVNA

Buy

52

out of 100

Grade: C-

Growth: 8.0Profit: 7.0Value: 4.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.18

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 8.7Quality: 5.8
Piotroski: 6/9Altman Z: 1.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CVNA.

GILDUndervalued (+44.2%)

Margin of Safety

+44.2%

Fair Value

$235.52

Current Price

$131.33

$104.19 discount

UndervaluedFair: $235.52Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVNA5 strengths · Avg: 9.4/10
Market CapQuality
$317.62B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
60.2%10/10

Every $100 of equity generates 60 in profit

Revenue GrowthGrowth
52.0%10/10

Revenue surging 52.0% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$166.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

CVNA2 concerns · Avg: 2.5/10
Profit MarginProfitability
6.4%3/10

6.4% margin — thin

P/E RatioValuation
231.2x2/10

Premium valuation, high expectations priced in

GILD2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.814/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CVNA

The strongest argument for CVNA centers on Market Cap, Return on Equity, Revenue Growth. Revenue growth of 52.0% demonstrates continued momentum.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : CVNA

The primary concerns for CVNA are Profit Margin, P/E Ratio. A P/E of 231.2x leaves little room for execution misses.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

CVNA profiles as a hypergrowth stock while GILD is a value play — different risk/reward profiles.

CVNA carries more volatility with a beta of 3.55 — expect wider price swings.

CVNA is growing revenue faster at 52.0% — sustainability is the question.

GILD generates stronger free cash flow (2.4B), providing more financial flexibility.

Bottom Line

GILD scores higher overall (72/100 vs 52/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Carvana Co

CONSUMER CYCLICAL · AUTO & TRUCK DEALERSHIPS · USA

Carvana Co., operates an e-commerce platform to buy and sell used cars in the United States. The company is headquartered in Tempe, Arizona.

Visit Website →

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?